Hikma Pharmaceuticals Regulatory News (HIK)

PRESS RELEASE

Hikma launches argatroban injection

London, 13 December 2012 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) ("Hikma"), the fast growing multinational pharmaceutical group, today announces the US launch of argatroban injection, following the approval of its New Drug Application (NDA) by the US Food and Drug Administration (FDA) earlier this year.

Hikma's argatroban is indicated for the prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) and as an anticoagulant in adult patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).

Said Darwazah, CEO of Hikma, said, "Hikma is pleased to be bringing argatroban injection to market. Argatroban will expand our injectables product line and help to differentiate our product portfolio in the US."

According to IMS Health, sales of argatroban injection were approximately $105 million for the 12 months ending October 2012. Hikma is marketing argatroban injection in 100mg/ml vials. Hikma's argatroban was developed through Hikma's partnership with the specialty pharmaceutical company, Exela Pharma Sciences, LLC.

----- ENDS -----

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, VP Corporate Strategy and Investor Relations

+44 (0)20 7399 2760/

FTI Consulting

Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole

+44 (0)20 7831 3113

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenues of $918 million and profit attributable to shareholders of $80.1 million.